Oruka Therapeutics, Inc. ORKA Allowance for unfunded lending related commitments

Allowance for unfunded lending related commitments at other companies

PNC Financial ServicesPNC

$201M+13.6%

Phillips 66PSX

$72M-20.9%

Bank of AmericaBAC

$1.16B+4.6%

Valley National BankVLY

$599.8M+1.0%

SouthStateSSB

$69.23M+11.2%

UBS

United BanksharesUBSI

$37.05M+1.3%

Other financials

Income statement

See full

Revenue-—

Operating income-$36.4M-45.2%

Net income-$31.8M-51.5%

EPS (diluted)-$0.46+93.4%

Balance sheet

See full

Cash & equivalents$49.5M-40.7%

Total debt$1.8M+90.8%

Total equity$486.7M+33.4%

Total assets$504.5M+33.8%

Cash flow

See full

Operating cash flow-$23.6M-13.0%

CapEx$73.0K+462%

Free cash flow-$23.7M-13.3%

Valuation

See full

Market cap$5.03B+533%

Returns & leverage

See full

Return on equity-27.3%-11.1pp

Debt / equity0×0.0×

Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther.

The official record: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s allowance for unfunded lending related commitments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s allowance for unfunded lending related commitments?: Oruka Therapeutics, Inc. (ORKA) reported allowance for unfunded lending related commitments of $1.08M in Q4 2025.